COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours
23/05/2025
OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours sur la modulation de l’immunité innée et l’activité antitumorale via le [...]
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025
23/05/2025
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025 BI [...]
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
23/05/2025
The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology 1 , with an initial focus on critically ill newborns and their parents. Whole genome [...]
AB Science :
23/05/2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR REALISE LE REGLEMENT-LIVRAISON DE SA DERNIERE AUGMENTATION DE CAPITAL POUR 1,8 MILLION D’EUROS Paris, 23 mai 2025, 8h AB Science S.A. (la “ Société ” ou “ AB Science ”, [...]
AB Science announces the settlement delivery of its latest capital increase for €1.8 million
23/05/2025
PRESS RELEASE AB SCIENCE ANNOUNCES THE SETTLEMENT DELIVERY OF ITS LATEST CAPITAL INCREASE FOR €1.8 MILLION Paris, May 23, 2025, 8am CET AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) [...]
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunies le 22 mai 2025
23/05/2025
Daix (France), New York City (New York, Etats-Unis), le 23 mai 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025
23/05/2025
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies [...]
Inventiva publie ses informations financières¹ du 1er trimestre 2025
23/05/2025
Trésorerie et équivalents de trésorerie à 67,9 millions d’euros Daix (France), New York City (New York, Etats-Unis), le 23 mai 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société [...]
Inventiva reports 2025 First Quarter Financial Information¹
23/05/2025
Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company [...]
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
23/05/2025
Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are not candidates for [...]
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
23/05/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new data from several studies of compounds [...]
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
23/05/2025
ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced [...]
Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition
23/05/2025
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug [...]
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
23/05/2025
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously [...]
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
22/05/2025
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has [...]
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
22/05/2025
Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002). Demonstrated favorable safety and tolerability profile: 4.88% serious adverse events vs. 6.45% for [...]
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
22/05/2025
ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today [...]
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
22/05/2025
Immix Biopharma today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety. – NXC-201 demonstrated a complete [...]
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
22/05/2025
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an [...]

Pages